NasdaqHealth CarePharmaceutical PreparationsNEW YORK, NY

iBio, Inc. IBIO

Ask your AI

The reported share count looks too low next to the company’s average share countCIK 1420720

Insider trades, 12 mo

4 buys · 0 sells

$98.1K bought, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

26.6% of shares · 11 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in iBio, Inc.'s latest quarterly report, compared with the one before.

Filed Nov 10, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-K for the period ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in iBio, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

4 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Mar 26, 2026. Insiders have two business days to file.

Recent insider trades

Marc Banjak Chief Legal Officer	Mar 26 Form 4 ↗	Buy	+$2,524 1,434 sh @ $1.76	-74.9%
Marc Banjak Chief Legal Officer	Mar 26 Form 4 ↗	Buy	+$20.5K 12,500 sh @ $1.64	-74.9%
Felipe Duran Chief Financial Officer	Mar 19 Form 4 ↗	Buy	+$50.2K 24,835 sh @ $2.02	-79.5%
Martin Brenner See Remarks, Director	Mar 19 Form 4 ↗	Buy	+$24.9K 12,336 sh @ $2.02	-79.5%
Felipe Duran Chief Financial Officer	Jan 10, 2025 Form 4 ↗	Buy	+$25.0K 9,191 sh @ $2.72	-101.3%

All IBIO insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

17.13M shares

33 funds report IBIO. Values checked against market prices.

Funds own 70% of shares (Q2 2026)

55 funds hold the stock.

Q3 2026: 27% · 5,560 of ~8,900 funds reported so far

Q2 202519%
Q3 202518%
Q4 202547%
Q1 202639%
Q2 202670%
Q3 2026 (so far)27%

Q3 2026. 6 new, 11 added to, 9 trimmed, 29 exited since Q2 2026.

Top 13F holders
#
1	Silverarc Capital Management, LLC 13F ↗	5.36M	$6.3M	+52.2%
2	Affinity Asset Advisors, LLC 13F ↗	4.13M	$4.9M	+3.1%
3	Vanguard Capital Management LLC 13F ↗	2.10M	$2.5M	unchanged
4	Ensign Peak Advisors, Inc 13F ↗	1.57M	$1.8M	-14.6%
5	Marshall Wace, LLP 13F ↗	766,195	$904.1K	-15.3%
6	Renaissance Technologies LLC 13F ↗	688,400	$812.3K	+239.4%
7	Geode Capital Management, LLC 13F ↗	525,983	$620.8K	+5.0%
8	Walleye Capital LLC 13F ↗	400,043	$472.1K	-20.1%
9	BlackRock, Inc. 13F ↗	291,450	$343.9K	+20.4%
10	Vanguard Fiduciary Trust Co 13F ↗	286,875	$338.5K	unchanged

Download CSV Every fund that holds IBIO, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What iBio, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What iBio, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report, adjusted for splits

Funds holding the stock by quarter

Q1 2023	1	—	0	$17
Q2 2023	1	0	0	$5
Q4 2023	21	+20	251,805	$345.1K
Q1 2024	28	+7	2.89M	$11.5M
Q2 2024	28	0	2.69M	$5.7M
Q3 2024	32	+4	2.61M	$5.8M
Q4 2024	30	-2	2.61M	$6.4M
Q1 2025	34	+4	2.59M	$10.4M
Q2 2025	30	-4	3.20M	$2.4M
Q3 2025	32	+2	3.57M	$3.0M
Q4 2025	50	+18	16.34M	$31.6M
Q1 2026	52	+2	19.43M	$36.9M
Q2 2026	55	+3	34.74M	$60.8M
Q3 2026	33	-22	17.13M	$20.2M

Each point is a quarter-end, from Q1 2023 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (451033708). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q1 2023) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits (1-for-20 on Nov 29, 2023): reports from before a split are multiplied by its ratio, so every quarter is on the share count of Q3 2026.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes21 in 12 mo 8-K events5 in 90 days Patents4 patents granted Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive pay3 fiscal years Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials2 active IPO history5 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: iBio, Inc.
Address: 600 MADISON AVENUE, SUITE 1601, NEW YORK, NY 10022-1737
Phone: 302 355-0650
Fiscal year ends: Jun 30
Filer category: Non-accelerated filer, smaller reporting company
Incorporated in: DE
Listed as: IBIO (Nasdaq)
Former names: iBio, Inc. (until 2026); iBioPharma, Inc. (until 2009); InB:Biotechnologies, Inc. (until 2008)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$0.7317−$0.03 (−4.00%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $0.707 · High $0.84Nov 13, 2026

Aug 13, 2026Low $0.707 · High $1.49Nov 13, 2026

Nov 13, 2025Low $0.707 · High $3.07Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.